Answers are grounded in this paper and cite their sources.
This study presents lipid-doped hydrogel microcarriers as a scalable, cost-effective oral delivery platform to improve the in vitro bioaccessibility and gastrointestinal stability of curcumin (CUR), a hydrophobic nutraceutical limited by low aqueous solubility and chemical instability. The system embeds CUR-loaded medium-chain lipid droplets, based on medium-chain monoglycerides (MCM) or medium-chain triglycerides (MCT), within surfactant mixed micelles and immobilizes them in a hydrogel matrix. In simulated gastrointestinal digestion, lipid droplets enhanced CUR dispersion and reduced its exposure to aqueous gastrointestinal fluids, while the hydrogel matrix mitigated CUR degradation during passage. MCM- and MCT-doped microparticles showed comparable size (1386–1715 µm), morphology (Scanning Electron Microscopy, SEM), encapsulation efficiency (over 87%), low moisture content (below 3%), and maintained physical stability under in vitro gastrointestinal conditions. Under simulated small-intestine conditions, MCM-doped microparticles exhibited a near zero-order release profile without an initial burst. Relative to free CUR, bioaccessibility increased 11-fold for MCM-doped microparticles and 6-fold for MCT-doped microparticles. In the solubilized small-intestinal fraction, MCM-doped microparticles achieved over 64% of released CUR in bioaccessible form, whereas MCT-doped microparticles reached 39.5–40.1%. All lipid-doped microparticles were buoyant (ρ < 0.948 g/cm³), suggesting potential for prolonged gastric residence (gastroretention), which may support controlled release during oral delivery by limiting premature CUR loss under gastric conditions and promoting solubilization under intestinal conditions.
No takes yet. Share an insight, caveat, or question.
Marta Tsirigotis‐Maniecka (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: